Global Medical Technology Leader Selects Kneat
Kneat (OTCQC: KSIOF) has secured a three-year Master Services Agreement with a global medical technology company, a division of a larger Asian manufacturer with over 30,000 employees operating in more than 160 countries. The client will implement the Kneat Gx platform for equipment validation processes.
CEO Eddie Ryan highlighted that this agreement reinforces the industry's confidence in Kneat's solutions within the life sciences sector. The company's growing platform functionality and adoption by major life sciences companies demonstrates Kneat's technical capabilities and strategic value in validation use cases.
Kneat (OTCQC: KSIOF) ha ottenuto un contratto di Servizi Master triennale con un'azienda globale di tecnologia medica, divisione di un grande produttore asiatico con oltre 30.000 dipendenti e presente in più di 160 paesi. Il cliente implementerà la piattaforma Kneat Gx per i processi di convalida delle apparecchiature.
Il CEO Eddie Ryan ha sottolineato che questo accordo rafforza la fiducia del settore nelle soluzioni di Kneat nel campo delle scienze della vita. La crescente funzionalità della piattaforma e l'adozione da parte di importanti aziende del settore dimostrano le capacità tecniche e il valore strategico di Kneat nei casi d'uso di convalida.
Kneat (OTCQC: KSIOF) ha asegurado un Acuerdo Maestro de Servicios por tres años con una empresa global de tecnología médica, una división de un gran fabricante asiático con más de 30,000 empleados que opera en más de 160 países. El cliente implementará la plataforma Kneat Gx para los procesos de validación de equipos.
El CEO Eddie Ryan destacó que este acuerdo refuerza la confianza de la industria en las soluciones de Kneat dentro del sector de ciencias de la vida. La creciente funcionalidad de la plataforma y su adopción por parte de grandes empresas del sector demuestran las capacidades técnicas y el valor estratégico de Kneat en casos de uso de validación.
Kneat (OTCQC: KSIOF)� 아시� 대� 제조업체 산하� 글로벌 의료 기술 회사와 3년간� 마스� 서비� 계약� 체결했습니다. � 회사� 30,000� 이상� 직원� 160개국 이상에서 운영되고 있습니다. 고객은 장비 검� 프로세스� Kneat Gx 플랫폼을 도입� 예정입니�.
CEO 에디 라이언은 이번 계약� 생명과학 분야에서 Kneat 솔루션에 대� 산업계의 신뢰� 강화한다� 강조했습니다. 플랫� 기능� 확장� 주요 생명과학 기업들의 도입은 Kneat� 기술력과 검� 사례에서� 전략� 가치를 입증합니�.
Kneat (OTCQC : KSIOF) a conclu un accord-cadre de services de trois ans avec une entreprise mondiale de technologie médicale, division d’un grand fabricant asiatique employant plus de 30 000 personnes et opérant dans plus de 160 pays. Le client mettra en œuvre la plateforme Kneat Gx pour les processus de validation des équipements.
Le PDG Eddie Ryan a souligné que cet accord renforce la confiance de l'industrie dans les solutions de Kneat dans le secteur des sciences de la vie. L’évolution des fonctionnalités de la plateforme et son adoption par des grandes entreprises du secteur démontrent les capacités techniques et la valeur stratégique de Kneat dans les cas d’utilisation de validation.
Kneat (OTCQC: KSIOF) hat einen dreijährigen Master-Service-Vertrag mit einem globalen Medizintechnikunternehmen abgeschlossen, einer Sparte eines großen asiatischen Herstellers mit über 30.000 Mitarbeitern, der in mehr als 160 Ländern tätig ist. Der Kunde wird die Kneat Gx-Plattform für Validierungsprozesse von Geräten einsetzen.
CEO Eddie Ryan betonte, dass diese Vereinbarung das Vertrauen der Branche in Kneats Lösungen im Bereich der Lebenswissenschaften stärkt. Die wachsende Funktionalität der Plattform und die Akzeptanz bei großen Unternehmen der Lebenswissenschaften zeigen Kneats technische Fähigkeiten und strategischen Wert in Validierungsanwendungen.
- Secured new three-year Master Services Agreement with global medical technology company
- Client has significant global presence across 160+ countries
- Demonstrates continued adoption by major life sciences companies
- None.
LIMERICK, Ireland, Aug. 07, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTCQC: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a global medical technology company (“the Company�) has signed a three-year Master Services Agreement with Kneat.
The Company is a division of a larger manufacturer, headquartered in Asia, that employs over 30,000 people and provides specialty technologies and medical devices in more than 160 countries worldwide. This Company will use the Kneat Gx platform initially for equipment validation.
“This new signing again underscores the confidence in Kneat within the life sciences sector,� said Eddie Ryan, Kneat CEO. “Our software platform continues to advance with growing functionality and is designed to deliver incremental value and benefits in the years to come.�
Adoption of Kneat by the world’s largest life sciences companies, and the large-scale, multi-site deployments within them, highlight Kneat’s technical fit for the breadth of validation use cases and the strategic trust that the most demanding customers place in Kneat’s platform.
About Kneat
Kneat Solutions provides leading companies in highly regulated industries with unparalleled efficiency in validation and compliance through its digital validation platform Kneat Gx. As an industry leader in customer satisfaction, Kneat boasts an excellent record for implementation, powered by our user-friendly design, expert support, and on-demand training academy. Kneat Gx is an industry-leading digital validation platform that enables highly regulated companies to manage any validation discipline from end-to-end. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. Multiple independent customer studies show up to
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein, certain information presented constitutes “forward-looking information� within the meaning of applicable Canadian securities laws. Such forward-looking information includes, but is not limited to, the relationship between Kneat and the customer, Kneat’s business development activities, the use and implementation timelines of Kneat’s software within the customer’s validation processes, the ability and intent of the customer to scale the use of Kneat’s software within the customer’s organization, and the compliance of Kneat’s platform under regulatory audit and inspection. While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties.
Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor’s own risk. For more information visit.
For further information:
Katie Keita, Kneat Investor Relations
P: + 1 902-450-2660
:
